Deutsche Bank Ag\ Inmune Bio, Inc. Transaction History

Deutsche Bank Ag\

$245 Billion
Q1 2025

A detailed history of Deutsche Bank Ag\ transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 38,011 shares of INMB stock, worth $277,480. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,011

Previous 109,848 65.4%

Holding current value

$277,480

Previous $512,000 42.19%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$4.93 - $10.48 $354,156 - $752,851	-71,837 Reduced 65.4%	38,011 $296,000
Q3 2023 Nov 09, 2023	SELL	$6.61 - $10.9 $74,032 - $122,080	-11,200 Reduced 9.25%	109,848 $743,000
Q2 2022 Aug 11, 2022	BUY	$5.48 - $8.97 $82,200 - $134,550	15,000 Added 14.14%	121,048 $1.07 Million
Q4 2021 Feb 11, 2022	SELL	$9.97 - $20.38 $79 - $163	-8 Reduced 0.01%	106,048 $1.08 Million
Q3 2021 Nov 04, 2021	BUY	$14.13 - $27.85 $113 - $222	8 Added 0.01%	106,056 $2.06 Million
Q1 2021 May 13, 2021	BUY	$11.61 - $26.85 $116,100 - $268,500	10,000 Added 10.41%	106,048 $1.26 Million
Q2 2020 Aug 13, 2020	BUY	$3.1 - $6.09 $124,000 - $243,600	40,000 Added 71.37%	96,048 $504,000
Q1 2020 May 14, 2020	BUY	$2.21 - $6.15 $22,100 - $61,500	10,000 Added 21.72%	56,048 $187,000
Q4 2019 Feb 14, 2020	BUY	$3.56 - $6.1 $16,785 - $28,761	4,715 Added 11.41%	46,048 $267,000
Q3 2019 Nov 14, 2019	BUY	$5.32 - $10.0 $42,560 - $80,000	8,000 Added 24.0%	41,333 $243,000
Q1 2019 May 15, 2019	BUY	$7.08 - $8.2 $235,997 - $273,330	33,333 New	33,333 $261,000

Others Institutions Holding INMB

# of Institutions

Shares Held

6.93M

Call Options Held

240K

Put Options Held

74.6K

View Full List

About Inmune Bio, Inc.

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $131M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

More about INMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account